Stockscreener 앱 받기
1.52
3.40%
0.05
시간 외 거래:
1.53
0.01
+0.66%
전일 마감가:
$1.47
열려 있는:
$1.48
하루 거래량:
840.83K
Relative Volume:
1.01
시가총액:
$87.06M
수익:
-
순이익/손실:
$-292.19M
주가수익비율:
-0.3348
EPS:
-4.54
순현금흐름:
$-208.41M
1주 성능:
+25.62%
1개월 성능:
+21.60%
6개월 성능:
-56.57%
1년 성능:
-86.28%
1일 변동 폭
$1.45
$1.56
1주일 범위
$1.19
$1.60
52주 변동 폭
$1.01
$11.16
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
명칭
Zentalis Pharmaceuticals Inc
전화
(858) 263-4333
주소
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
ZNTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.52 | 87.06M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-12 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2024-06-20 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-06-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2024-06-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-11-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | 개시 | Cowen | Outperform |
| 2022-04-06 | 개시 | Wells Fargo | Overweight |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-29 | 개시 | Oppenheimer | Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-01-20 | 개시 | Wedbush | Outperform |
| 2020-09-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-08-27 | 개시 | H.C. Wainwright | Buy |
| 2020-04-28 | 개시 | Guggenheim | Buy |
| 2020-04-28 | 개시 | Jefferies | Buy |
| 2020-04-28 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 개시 | SVB Leerink | Outperform |
모두보기
Zentalis Pharmaceuticals Inc 주식(ZNTL)의 최신 뉴스
Ameriprise Financial Inc. Purchases New Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies - The Globe and Mail
ProShare Advisors LLC Lowers Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Nuveen Asset Management LLC Has $1.94 Million Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Deutsche Bank AG Grows Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Two Sigma Investments LP Sells 291,801 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock News - GuruFocus
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Expands Cancer Research Team: 137K Share Options Granted to Key New Hires - Stock Titan
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Acquired by Millennium Management LLC - Defense World
Northern Trust Corp Raises Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
BNP Paribas Financial Markets Invests $534,000 in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Captrust Financial Advisors Buys New Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Analysts - Defense World
Jane Street Group LLC Boosts Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals at H.C. Wainwright BioConnect Conference - TipRanks
Balyasny Asset Management L.P. Has $175,000 Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Wedbush Issues Optimistic Outlook for ZNTL Earnings - Defense World
Wedbush Reaffirms Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals First Quarter 2025 Earnings: US$0.67 loss per share (vs US$0.14 profit in 1Q 2024) - Yahoo Finance
Zentalis Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
ZNTL Advances Azenosertib Development Amid Strategic Progress | - GuruFocus
Analyst Reiterates Neutral Rating for Zentalis Pharma (ZNTL) | Z - GuruFocus
ZNTL: Oppenheimer Adjusts Price Target Amid Regulatory Developme - GuruFocus
ZNTL: Oppenheimer Adjusts Price Target Amid Regulatory Developments | ZNTL Stock News - GuruFocus
Zentalis Pharma (ZNTL) Receives Buy Rating from HC Wainwright & Co. | ZNTL Stock News - GuruFocus
22,440 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Bought by Raymond James Financial Inc. - Defense World
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress - GlobeNewswire
Zentalis Pharmaceuticals Inc (ZNTL) Q1 2025 Earnings: EPS Misses at -$0.67, Revenue Meets Estimate at $0.00 Million - GuruFocus
Zentalis Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Barclays PLC Grows Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
An analyst sees good growth prospects for Zentalis Pharmaceuticals Inc (ZNTL) - Sete News
Zentalis Pharmaceuticals Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock News - GuruFocus
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Expands Cancer Drug Development Team with Strategic New Hire Grant Worth $20,000 - Stock Titan
Was anything positive for Zentalis Pharmaceuticals Inc (ZNTL) stock last session? - uspostnews.com
Zentalis Pharmaceuticals Inc [ZNTL] Director makes an insider purchase of 21,000 shares worth 29373.0. - knoxdaily.com
Zentalis pharmaceuticals director Scott Myers acquires $29,372 in stock By Investing.com - Investing.com Canada
Zentalis pharmaceuticals director Scott Myers acquires $29,372 in stock - Investing.com Australia
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock - Yahoo Finance
Ratios Revealed: Decoding Zentalis Pharmaceuticals Inc (ZNTL)’s Financial Health - DWinneX
Zentalis shares insights on cancer research at AACR - Investing.com Australia
Zentalis (ZNTL) Advances with Phase 2 Trial in Ovarian Cancer | - GuruFocus
Zentalis shares insights on cancer research at AACR By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals Doses 1st Patient in Part 2 of Ovarian Cancer Clinical Trial - marketscreener.com
Zentalis Doses First Patient In Phase 2 DENALI Trial Of Azenosertib In Cyclin E1+ PROC - Nasdaq
Zentalis Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
Breakthrough: New Cancer Drug Achieves 35% Response Rate in Hard-to-Treat Ovarian Cancer Patients - Stock Titan
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Purchased by Geode Capital Management LLC - Defense World
Zentalis Pharmaceuticals Inc (ZNTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Zentalis Pharmaceuticals Inc 주식 (ZNTL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
1.21%
1.51%
자본화:
|
볼륨(24시간):